This technology provides methods for treating myelofibrosis using targets that deplete or inhibit the expansion of Sox10+ and ErbB3+ glial cells.
Myelofibrosis is a rare blood cancer characterized by the formation of scar tissue in bone marrow, often attributed to mutations in hematopoietic stem cells that result in abnormal cell growth. To date, the only approved myelofibrosis treatment is JAK inhibitors, but these drugs have not been effective in mitigating disease progression. Hematopoietic stem cell transplants are an alternative treatment option, but these procedures come with a high cost and elevated risk. Therefore, it is necessary to develop more effective and accessible treatments for patients diagnosed with myelofibrosis.
This technology identifies a population of Sox10+ and ErbB3+ glial cells in the bone marrow that expand during myelofibrosis pathogenesis and proposes a treatment strategy that inhibits the proliferation of these cells. Depletion or inhibition of Sox10+ and ErbB3+ glial cells through pharmacological agents can reduce the incidence of myelofibrosis development or halt the progression of related pathologies.
This technology has been validated with mouse models.
Patent Pending(US20240342116)
IR CU23243
Licensing Contact: Kristin Neuman
